Loading...
Market
What will TECELRA's market share be among cell therapies for solid tumors by the end of 2025?
2
Resolution / Starting Odds
Less than 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
More than 30% • 25%
Market analysis reports from reputable sources like Gartner, Frost & Sullivan, or industry reports
Story
FDA Grants Accelerated Approval to Adaptimmune's TECELRA, First Engineered Cell Therapy for Solid Tumor
Aug 2, 2024, 09:45 AM
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Adaptimmune's TECELRA® (afamitresgene autoleucel), marking the first approved engineered cell therapy for a solid tumor. This gene therapy is indicated for the treatment of adults with unresectable or metastatic synovial sarcoma, a rare form of cancer that develops in the soft tissues of the body. The approval represents a significant milestone for the oncology community, extending the power of immunotherapies into difficult-to-reach sarcomas. Patients eligible for this treatment must have tumors expressing MAGE-A4 and be positive for HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P.
View original story
Similar markets
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Advanced Synovial Sarcoma • 25%
Other Sarcomas • 25%
Other Solid Tumors • 25%
Combination Therapies • 25%
Less than 10% • 25%
10% to 19% • 25%
20% to 29% • 25%
30% or more • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 20% • 25%
More than 20% • 25%
0-10% • 25%
10-20% • 25%
20-30% • 25%
30% or more • 25%
Less than 5% • 25%
5% - 10% • 25%
10% - 15% • 25%
More than 15% • 25%
Below 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
Above 30% • 25%
Leading • 25%
Second • 25%
Third • 25%
Lower • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%